檢索結果 - Tebbutt, Niall C

Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature 由 Chan, David L., Pavlakis, Nick, Shapiro, Jeremy, Price, Timothy J., Karapetis, Christos S., Tebbutt, Niall C., Segelov, Eva

獲取全文 獲取全文 獲取全文

Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature 由 Chan, David L., Pavlakis, Nick, Shapiro, Jeremy, Price, Timothy J., Karapetis, Christos S., Tebbutt, Niall C., Segelov, Eva

獲取全文 獲取全文 獲取全文

Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials 由 Hurwitz, Herbert I., Tebbutt, Niall C., Kabbinavar, Fairooz, Giantonio, Bruce J., Guan, Zhong-Zhen, Mitchell, Lada, Waterkamp, Daniel, Tabernero, Josep

獲取全文 獲取全文 獲取全文

Severe combined hyperlipidaemia and retinal lipid infiltration in a patient with Type 2 diabetes mellitus 由 Davey, Rachel A, Tebbutt, Niall C, Favaloro, Jenny M, O'Neal, David N, Rae, Derek, Zajac, Jeffrey D, Best, James D

獲取全文 獲取全文 獲取全文

A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction 由 Shah, Manish A., Cho, Jae-Yong, Tan, Iain B., Tebbutt, Niall C., Yen, Chia-Jui, Kang, Alice, Shames, David S., Bu, Lilian, Kang, Yoon-Koo

獲取全文 獲取全文 獲取全文

K‐Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines 由 Yeung, Yvonne, Lau, David K., Chionh, Fiona, Tran, Hoanh, Tse, Janson W. T., Weickhardt, Andrew J., Nikfarjam, Mehrdad, Scott, Andrew M., Tebbutt, Niall C., Mariadason, John M.

獲取全文 獲取全文 獲取全文

Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study 由 Lau, David K., Tay, Rebecca Y., Yeung, Yvonne H., Chionh, Fiona, Mooi, Jennifer, Murone, Carmel, Skrinos, Effie, Price, Timothy J., Mariadason, John M., Tebbutt, Niall C.

獲取全文 獲取全文 獲取全文

Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab* 由 Price, Timothy J, Hardingham, Jennifer E, Lee, Chee K, Townsend, Amanda R, Wrin, Joseph W, Wilson, Kate, Weickhardt, Andrew, Simes, Robert J, Murone, Carmel, Tebbutt, Niall C

獲取全文 獲取全文 獲取全文

The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT] 由 Clarke, Stephen John, Burge, Matthew, Feeney, Kynan, Gibbs, Peter, Jones, Kristian, Marx, Gavin, Molloy, Mark P., Price, Timothy, Reece, William H. H., Segelov, Eva, Tebbutt, Niall C.

獲取全文 獲取全文 獲取全文

Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial 由 Klein, Oliver, Kee, Damien, Nagrial, Adnan, Markman, Ben, Underhill, Craig, Michael, Michael, Jackett, Louise, Lum, Caroline, Behren, Andreas, Palmer, Jodie, Tebbutt, Niall C., Carlino, Matteo S., Cebon, Jonathan

獲取全文 獲取全文 獲取全文

Glycoprotein A33 deficiency: a new mouse model of impaired intestinal epithelial barrier function and inflammatory disease 由 Williams, Benjamin B., Tebbutt, Niall C., Buchert, Michael, Putoczki, Tracy L., Doggett, Karen, Bao, Shisan, Johnstone, Cameron N., Masson, Frederick, Hollande, Frederic, Burgess, Antony W., Scott, Andrew M., Ernst, Matthias, Heath, Joan K.

獲取全文 獲取全文 獲取全文

The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors 由 Rosen, Lee S, Lipton, Lara, Price, Timothy J, Belman, Neil D, Boccia, Ralph V, Hurwitz, Herbert I, Stephenson Jr, Joe J, Wirth, Lori J, McCoy, Sheryl, Hei, Yong-jiang, Hsu, Cheng-Pang, Tebbutt, Niall C

獲取全文 獲取全文 獲取全文

Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial 由 Tebbutt, Niall C, Price, Timothy J, Ferraro, Danielle A, Wong, Nicole, Veillard, Anne-Sophie, Hall, Merryn, Sjoquist, Katrin M, Pavlakis, Nick, Strickland, Andrew, Varma, Suresh C, Cooray, Prasad, Young, Rosemary, Underhill, Craig, Shannon, Jennifer A, Ganju, Vinod, Gebski, Val

獲取全文 獲取全文 獲取全文

DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis 由 Tögel, Lars, Nightingale, Rebecca, Wu, Rui, Chüeh, Anderly C., Al-Obaidi, Sheren, Luk, Ian, Dávalos-Salas, Mercedes, Chionh, Fiona, Murone, Carmel, Buchanan, Daniel D., Chatterton, Zac, Sieber, Oliver M., Arango, Diego, Tebbutt, Niall C., Williams, David, Dhillon, Amardeep S., Mariadason, John M.

獲取全文 獲取全文 獲取全文

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer 由 Cutsem, Eric Van, Eng, Cathy, Nowara, Elzbieta, Świeboda-Sadlej, Anna, Tebbutt, Niall C., Mitchell, Edith, Davidenko, Irina, Stephenson, Joe, Elez, Elena, Prenen, Hans, Deng, Hongjie, Tang, Rui, McCaffery, Ian, Oliner, Kelly S., Chen, Lisa, Gansert, Jennifer, Loh, Elwyn, Smethurst, Dominic, Tabernero, Josep

獲取全文 獲取全文 獲取全文

Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers 由 Herbertson, Rebecca A., Tebbutt, Niall C., Lee, Fook-Thean, MacFarlane, David J., Chappell, Bridget, Micallef, Noel, Lee, Sze-Ting, Saunder, Timothy, Hopkins, Wendie, Smyth, Fiona E., Wyld, David K., Bellen, John, Sonnichsen, Daryl S., Brechbiel, Martin W., Murone, Carmel, Scott, Andrew M.

獲取全文 獲取全文 獲取全文

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer 由 Chionh, Fiona, Gebski, Val, Al-Obaidi, Sheren J., Mooi, Jennifer K., Bruhn, Maressa A., Lee, Chee K., Chüeh, Anderly C., Williams, David S., Weickhardt, Andrew J., Wilson, Kate, Scott, Andrew M., Simes, John, Hardingham, Jennifer E., Price, Timothy J., Mariadason, John M., Tebbutt, Niall C.

獲取全文 獲取全文 獲取全文

RHOA inactivation enhances Wnt signaling and promotes colorectal cancer 由 Rodrigues, Paulo, Macaya, Irati, Bazzocco, Sarah, Mazzolini, Rocco, Andretta, Elena, Dopeso, Higinio, Mateo-Lozano, Silvia, Bilić, Josipa, Cartón-García, Fernando, Nieto, Rocio, Suárez-López, Lucia, Afonso, Elsa, Landolfi, Stefania, Hernandez-Losa, Javier, Kobayashi, Kazuto, Cajal, Santiago Ramón y, Tabernero, Josep, Tebbutt, Niall C., Mariadason, John M., Schwartz, Simo, Arango, Diego

獲取全文 獲取全文 獲取全文

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, dou... 由 Catenacci, Daniel V T, Tebbutt, Niall C, Davidenko, Irina, Murad, André M, Al-Batran, Salah-Eddin, Ilson, David H, Tjulandin, Sergei, Gotovkin, Evengy, Karaszewska, Boguslawa, Bondarenko, Igor, Tejani, Mohamedtaki A, Udrea, Anghel A, Tehfe, Mustapha, De Vita, Ferdinando, Turkington, Cheryl, Tang, Rui, Ang, Agnes, Zhang, Yilong, Hoang, Tien, Sidhu, Roger, Cunningham, David

獲取全文 獲取全文 獲取全文

Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study 由 Ohtsu, Atsushi, Ajani, Jaffer A., Bai, Yu-Xian, Bang, Yung-Jue, Chung, Hyun-Cheol, Pan, Hong-Ming, Sahmoud, Tarek, Shen, Lin, Yeh, Kun-Huei, Chin, Keisho, Muro, Kei, Kim, Yeul Hong, Ferry, David, Tebbutt, Niall C., Al-Batran, Salah-Eddin, Smith, Heind, Costantini, Chiara, Rizvi, Syed, Lebwohl, David, Van Cutsem, Eric

獲取全文 獲取全文 獲取全文